Knockdown of the interleukin-6 receptor alpha chain of dendritic cell vaccines enhances the therapeutic potential against IL-6 producing tumors

Wonchan Hwang, Keunok Jung, Youkyoung Jeon, Shik Yun, Tae Woo Kim, Inhak Choi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Tumor microenvironment has emerged as one of the major obstacles against the clinical efficacy of dendritic cell (DC) vaccines. Tumor-derived IL-6 may inhibit the differentiation of hematopoietic progenitor cells into DCs and suppress DC maturation, rendering DCs tolerogenic. We hypothesized that silencing the IL-6 receptor alpha chain (IL-6Rα) would restore the functional competence of DC vaccines in mice with an IL-6-producing TC-1 tumor, and eventually give rise to protective immunity. We found that the IL-6Rα knockdown-DC vaccine significantly enhanced the frequency of tumor-specific CD8 + CTLs-producing effector molecules such as IFN-γ, TNF-α, FasL, perforin, and granzyme B, and generated more CD8 + memory T cells, leading to the substantially prolonged survival of TC-1 tumor-bearing mice.

Original languageEnglish
Pages (from-to)34-44
Number of pages11
JournalVaccine
Volume29
Issue number1
DOIs
Publication statusPublished - 2010 Dec 10

Fingerprint

dendritic cells
interleukin-6
Dendritic Cells
Interleukin-6
Vaccines
vaccines
Interleukin-6 Receptors
therapeutics
receptors
neoplasms
Neoplasms
Tumor Microenvironment
Therapeutics
Hematopoietic Stem Cells
Mental Competency
mice
rendering
Immunity
T-Lymphocytes
T-lymphocytes

Keywords

  • Dendritic cell vaccine
  • IL-6 receptor
  • Knockdown

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Knockdown of the interleukin-6 receptor alpha chain of dendritic cell vaccines enhances the therapeutic potential against IL-6 producing tumors. / Hwang, Wonchan; Jung, Keunok; Jeon, Youkyoung; Yun, Shik; Kim, Tae Woo; Choi, Inhak.

In: Vaccine, Vol. 29, No. 1, 10.12.2010, p. 34-44.

Research output: Contribution to journalArticle

Hwang, Wonchan ; Jung, Keunok ; Jeon, Youkyoung ; Yun, Shik ; Kim, Tae Woo ; Choi, Inhak. / Knockdown of the interleukin-6 receptor alpha chain of dendritic cell vaccines enhances the therapeutic potential against IL-6 producing tumors. In: Vaccine. 2010 ; Vol. 29, No. 1. pp. 34-44.
@article{596f831acf584b5681e6a76e877b7646,
title = "Knockdown of the interleukin-6 receptor alpha chain of dendritic cell vaccines enhances the therapeutic potential against IL-6 producing tumors",
abstract = "Tumor microenvironment has emerged as one of the major obstacles against the clinical efficacy of dendritic cell (DC) vaccines. Tumor-derived IL-6 may inhibit the differentiation of hematopoietic progenitor cells into DCs and suppress DC maturation, rendering DCs tolerogenic. We hypothesized that silencing the IL-6 receptor alpha chain (IL-6Rα) would restore the functional competence of DC vaccines in mice with an IL-6-producing TC-1 tumor, and eventually give rise to protective immunity. We found that the IL-6Rα knockdown-DC vaccine significantly enhanced the frequency of tumor-specific CD8 + CTLs-producing effector molecules such as IFN-γ, TNF-α, FasL, perforin, and granzyme B, and generated more CD8 + memory T cells, leading to the substantially prolonged survival of TC-1 tumor-bearing mice.",
keywords = "Dendritic cell vaccine, IL-6 receptor, Knockdown",
author = "Wonchan Hwang and Keunok Jung and Youkyoung Jeon and Shik Yun and Kim, {Tae Woo} and Inhak Choi",
year = "2010",
month = "12",
day = "10",
doi = "10.1016/j.vaccine.2010.10.027",
language = "English",
volume = "29",
pages = "34--44",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Knockdown of the interleukin-6 receptor alpha chain of dendritic cell vaccines enhances the therapeutic potential against IL-6 producing tumors

AU - Hwang, Wonchan

AU - Jung, Keunok

AU - Jeon, Youkyoung

AU - Yun, Shik

AU - Kim, Tae Woo

AU - Choi, Inhak

PY - 2010/12/10

Y1 - 2010/12/10

N2 - Tumor microenvironment has emerged as one of the major obstacles against the clinical efficacy of dendritic cell (DC) vaccines. Tumor-derived IL-6 may inhibit the differentiation of hematopoietic progenitor cells into DCs and suppress DC maturation, rendering DCs tolerogenic. We hypothesized that silencing the IL-6 receptor alpha chain (IL-6Rα) would restore the functional competence of DC vaccines in mice with an IL-6-producing TC-1 tumor, and eventually give rise to protective immunity. We found that the IL-6Rα knockdown-DC vaccine significantly enhanced the frequency of tumor-specific CD8 + CTLs-producing effector molecules such as IFN-γ, TNF-α, FasL, perforin, and granzyme B, and generated more CD8 + memory T cells, leading to the substantially prolonged survival of TC-1 tumor-bearing mice.

AB - Tumor microenvironment has emerged as one of the major obstacles against the clinical efficacy of dendritic cell (DC) vaccines. Tumor-derived IL-6 may inhibit the differentiation of hematopoietic progenitor cells into DCs and suppress DC maturation, rendering DCs tolerogenic. We hypothesized that silencing the IL-6 receptor alpha chain (IL-6Rα) would restore the functional competence of DC vaccines in mice with an IL-6-producing TC-1 tumor, and eventually give rise to protective immunity. We found that the IL-6Rα knockdown-DC vaccine significantly enhanced the frequency of tumor-specific CD8 + CTLs-producing effector molecules such as IFN-γ, TNF-α, FasL, perforin, and granzyme B, and generated more CD8 + memory T cells, leading to the substantially prolonged survival of TC-1 tumor-bearing mice.

KW - Dendritic cell vaccine

KW - IL-6 receptor

KW - Knockdown

UR - http://www.scopus.com/inward/record.url?scp=78649688852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649688852&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.10.027

DO - 10.1016/j.vaccine.2010.10.027

M3 - Article

VL - 29

SP - 34

EP - 44

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 1

ER -